Dutch Criteria for Familial Hypercholesterolemia (FH)

ورودی‌های بالینی بیمار

حداقل ۰ — حداکثر ۳۰ • واحد: mmol/L

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
dutch fh score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Unlikely FH0–2
  • Possible FH3–5
  • Probable FH6–7
  • Definite FH8–15
Direct Clinical Answer

The Dutch Criteria for Familial Hypercholesterolemia (FH) calculates evaluating glycemic control, metabolic decompensation severity, and long-term endocrine risks. Key inputs include ldl cholesterol mmol. Scores guide titrating insulin infusion protocols, managing fluid-electrolyte resuscitation, and long-term risk reduction. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Diagnoses familial hypercholesterolemia (FH) based on clinical, genetic, and family history using the Dutch Lipid Clinic Network (DLCN) point-based scoring system. Provides stratification into possible, probable, or definite FH categories.

Clinical Indication

The Dutch Criteria for Familial Hypercholesterolemia (FH) is indicated for bedside clinical practice to support Diagnoses familial hypercholesterolemia (FH) based on clinical, genetic, and family history using the Dutch Lipid Clinic Network (DLCN) point-based scoring system. Provides stratification into possible, probable, or definite FH categories.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with diabetes mellitus, diabetic ketoacidosis (DKA), hyperosmolar hyperglycemic state, thyroid storm, or adrenal crisis. Clinical application is indicated across Endocrinology clinics, inpatient metabolic services, and acute diabetes care units.

Limitations & Contraindications

Severe hyperglycemia lowers measured serum sodium; corrected sodium equations must guide intravenous fluid selection.

Clinical Pearls & Action Plan

Serial monitoring of serum electrolytes, potassium kinetics, venous pH, and anion gap is mandatory during acute metabolic crisis management. Guideline pearl: Widely recommended by international guidelines including ESC/EAS and NLA recommendations..

Formula & Variables:

Points awarded for: LDL cholesterol levels (1-8 points based on level), tendon xanthomas (6 points), corneal arcus <45 years (4 points), family history of elevated LDL (1 point), family history of premature CHD (1 point), personal premature CHD (2 points), personal premature CVD (1 point), positive DNA analysis (8 points). Scoring: 0-2 points = Unlikely FH, 3-5 points = Possible FH, 6-7 points = Probable FH, ≥8 points = Definite FH.

Input Parameters

NameTypeRequiredDescription
ldl_cholesterol_mmolfloatYesLDL cholesterol level in mmol/L(mmol/L)
tendon_xanthomasstringYesPresence of tendon xanthomas (Achilles tendon or dorsum of hand)
corneal_arcusstringYesCorneal arcus in patient <45 years old
family_history_ldlstringYesFamily history of LDL cholesterol >4.9 mmol/L (190 mg/dL) in adult first-degree relative or >4.0 mmol/L (155 mg/dL) in child/sibling <18 years
family_history_chdstringYesFamily history of premature coronary heart disease (CHD) in first-degree relative (men <55 years, women <60 years)
personal_chdstringYesPersonal history of premature coronary heart disease (men <55 years, women <60 years)
personal_cvdstringYesPersonal history of premature cerebral or peripheral vascular disease (men <55 years, women <60 years)
dna_analysisstringYesDNA analysis results: functional mutation in LDLR, APOB, or PCSK9 gene

Score Interpretation & Guidance

RangeStageDescription
0–2Unlikely FHFH unlikely
3–5Possible FHPossible familial hypercholesterolemia
6–7Probable FHProbable familial hypercholesterolemia
8–15Definite FHDefinite familial hypercholesterolemia

Evidence-Based References (EBM)

  • The diagnosis and management of familial hypercholesterolaemia. Dutch Health Care Insurance Board. 1999. Available from: https://www.lipidclinic.org/
  • Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478-90a. doi: 10.1093/eurheartj/eht273.DOI: 10.1093/eurheartj/eht273
  • Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014;35(32):2146-57. doi: 10.1093/eurheartj/ehu274.DOI: 10.1093/eurheartj/ehu274

Related calculators